NDAINJECTIONINJECTABLE
Approved
May 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OPTIRAY 320 (ioversol) by Guerbet is x-ray contrast activity [moa]. First approved in 1998.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPTIRAY 320 (ioversol) is a radiographic contrast agent administered by injection to enhance visualization during X-ray imaging procedures. It is indicated for patients with renal impairment, coronary artery disease, diabetes mellitus, and hypothyroidism undergoing diagnostic imaging. The drug works through X-ray contrast activity to improve radiological image quality.
LOE Approaching
As LOE approaches, commercial teams face portfolio transition pressure; expect consolidation of marketing resources and focus on retention-based strategies rather than growth initiatives.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
OPTIRAY 320 offers limited career growth opportunities given its LOE approaching status and minimal linked job postings; roles focus on mature product management, customer retention, and reimbursement defense. Professionals joining this team should expect portfolio transition work rather than expansive launch or growth initiatives.
Brand Manager
Worked on OPTIRAY 320 at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.